Latest Health News

Bio-Gene Technology’s novel acaricide Flavocide demonstrated over 90% mortality against Lyme disease-carrying ticks in lab tests presented by Purdue University, highlighting its potential in public health applications.

Alcidion Group has expanded its contract with North Cumbria Integrated Care NHS Foundation Trust to integrate MediViewer into its Miya Precision electronic patient record system, enhancing access to scanned and historical documents.

Clover Corporation posted a robust 38% revenue increase to $86 million in FY25, driven by product innovation and operational gains, while declaring a final dividend. The company’s cautious outlook for FY26 reflects ongoing regulatory and production challenges.

Clover Corporation Limited has reported a robust financial year ending July 2025, with revenue climbing 38% and net profit soaring to $7 million. The company also announced a higher fully franked final dividend, reflecting its strengthened financial position.

Emyria secures a multi-year funding agreement with Medibank to support its Treatment-Resistant Depression program, marking a first for insurer-backed psychotherapy in Australia.

Lakes Blue Energy reports strong gas shows at its Wombat-5 well in Victoria’s Gippsland Basin, reinforcing hopes for a commercially viable gas development.

RooLife Group has secured a $64 million two-year supply agreement to distribute its branded coffee and food products in China, reinforcing its expansion strategy in the fast-growing market.

HeraMED is fast-tracking its AI-driven maternity care technologies, including an early release of its AI Clinician Assistant and predictive models for high-risk pregnancies, aiming to revolutionize digital women’s health globally.

Cochlear Limited has updated its dividend details, confirming a fully franked ordinary dividend of AUD 2.15 per share for the first half of 2025, with payments available in multiple currencies based on shareholder location.

LTR Pharma has acquired a one-third equity stake in LevOmega Pty Ltd at no cost to shareholders, positioning itself in the growing pharmaceutical-grade omega-3 sector. This strategic move complements LTR’s existing intranasal pharmaceutical portfolio and aligns with its innovation-driven growth strategy.

EVE Health Group has begun distributing Dyspro™, a novel cannabinoid-based treatment for dysmenorrhoea and endometriosis, through a national telehealth partnership. This launch targets a significant unmet need in women’s health with a growing global market.

XPON Technologies announces a significant leadership reshuffle with founder Matt Forman stepping down as CEO due to health reasons, while Mark Simari assumes the role of Executive Chair amid strategic growth initiatives.